Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $130.00

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price objective boosted by Robert W. Baird from $123.00 to $130.00 in a research note issued to investors on Tuesday morning, MarketBeat.com reports. Robert W. Baird currently has an outperform rating on the stock.

Several other equities analysts have also recently commented on the stock. Weiss Ratings raised shares of Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research note on Thursday, August 6th. HC Wainwright increased their price target on shares of Mirum Pharmaceuticals from $140.00 to $195.00 and gave the company a “buy” rating in a research report on Monday. Royal Bank Of Canada dropped their target price on Mirum Pharmaceuticals from $148.00 to $135.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. UBS Group set a $137.00 price target on Mirum Pharmaceuticals in a research note on Thursday, August 27th. Finally, Citizens Jmp reissued a “market outperform” rating and set a $137.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Mirum Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $142.56.

Mirum Pharmaceuticals Stock Down 1.8%

MIRM stock opened at $83.92 on Tuesday. The stock has a fifty day moving average of $98.55 and a 200-day moving average of $101.37. Mirum Pharmaceuticals has a fifty-two week low of $63.23 and a fifty-two week high of $130.00. The company has a market capitalization of $5.45 billion, a price-to-earnings ratio of -5.77 and a beta of 0.61. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.86.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The business had revenue of $176.24 million for the quarter, compared to analysts’ expectations of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. Mirum Pharmaceuticals’s revenue for the quarter was up 37.9% compared to the same quarter last year. During the same period last year, the company earned ($0.12) earnings per share. As a group, equities research analysts predict that Mirum Pharmaceuticals will post -1.31 earnings per share for the current year.

Insider Activity

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 30,000 shares of the company’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $98.68, for a total transaction of $2,960,400.00. Following the transaction, the chief executive officer owned 194,440 shares in the company, valued at approximately $19,187,339.20. This represents a 13.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 40,000 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $100.00, for a total value of $4,000,000.00. Following the completion of the transaction, the senior vice president owned 1,274 shares in the company, valued at approximately $127,400. This trade represents a 96.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 123,499 shares of company stock worth $12,854,484 over the last three months. 8.32% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Engineers Gate Manager LP raised its holdings in Mirum Pharmaceuticals by 218.2% during the second quarter. Engineers Gate Manager LP now owns 8,143 shares of the company’s stock valued at $953,000 after acquiring an additional 5,584 shares during the period. Insight Wealth Partners LLC bought a new stake in Mirum Pharmaceuticals during the 2nd quarter valued at approximately $395,000. Integrated Wealth Concepts LLC bought a new stake in Mirum Pharmaceuticals during the 2nd quarter valued at approximately $27,000. Arizona State Retirement System lifted its holdings in Mirum Pharmaceuticals by 12.6% in the 2nd quarter. Arizona State Retirement System now owns 11,655 shares of the company’s stock worth $1,364,000 after purchasing an additional 1,306 shares in the last quarter. Finally, Nykredit A S bought a new position in Mirum Pharmaceuticals in the 2nd quarter worth approximately $247,000.

Key Stories Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Mirum’s Atebrioz, a potentially important catalyst that expands the company’s commercial portfolio and could improve future revenue and earnings prospects. Mirum wins FDA approval for Atebrioz
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $195 price target, well above the current trading level. The firm raised its EPS forecasts for Q3 2026 to $0.07 from a prior loss estimate of $0.31, FY2028 to $5.38 from $3.96, FY2029 to $7.21 from $5.71, and FY2030 to $10.03 from $7.12. These revisions signal stronger expected profitability as Mirum’s products mature. Mirum Pharmaceuticals stock price expected to rise
• Neutral Sentiment: A head-to-head comparison of Mirum and Sarepta Therapeutics provides broader investment context but does not represent a direct change to Mirum’s earnings, operations, or outlook. Mirum Pharmaceuticals and Sarepta Therapeutics head-to-head survey
• Negative Sentiment: HC Wainwright trimmed its Q3 2027 EPS forecast to $0.35 from $0.40, indicating some near-term uncertainty despite the firm’s substantially higher long-term earnings estimates. Mirum remains expected to post a full-year loss of $1.31 per share in the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for rare diseases of the liver and gastrointestinal system. The company’s work centers on conditions involving impaired bile acid transport and cholestasis, which can cause serious liver damage and debilitating symptoms such as itching.

Mirum’s primary commercial product is Livmarli (maralixibat), an oral ileal bile acid transporter inhibitor. In the United States, Livmarli is approved to treat cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible pediatric patients.